300573.SZ
兴齐眼药
SZSE · Healthcare · C 制造业 · CN
CNY 38.52
−3.09%Year over year
Reported trailing growth
- Revenue
- +23.0%
- EBITDA
- —
- EBIT
- +57.8%
- EPS
- +68.3%
- Free cash flow
- +59.8%
- Operating cash flow
- +47.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +25.5%
- EBITDA
- +42.4%
- EBIT
- +48.7%
- Net income
- +48.7%
- EPS
- +18.1%
- Free cash flow
- +194.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026